ストックスクリーナーアプリを入手
1.14
0.88%
0.01
アフターアワーズ：
1.14
前日終値:
$1.13
開ける：
$1.12
24時間の取引高:
39,680
Relative Volume:
0.56
時価総額：
$31.24M
収益：
-
当期純損益:
$-37.38M
株価収益率:
-0.9139
EPS:
-1.2474
ネットキャッシュフロー:
$-35.50M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
+1.79%
6か月 パフォーマンス:
+3.64%
1年 パフォーマンス:
-12.98%
1日の値動き範囲:
$1.1144
$1.225
1週間の範囲:
$1.1144
$1.23
52週間の値動き範囲:
$1.01
$1.55
An 2 Therapeutics Inc Stock (ANTX) Company Profile
名前
An 2 Therapeutics Inc
セクター
電話
(650) 331-9090
住所
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
ANTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.14 | 30.96M | 0 | -37.38M | -35.50M | -1.2474 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2024-08-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-12 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
すべてを表示
An 2 Therapeutics Inc (ANTX) 最新ニュース
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewswire
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with - The Manila Times
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance
Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView — Track All Markets
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - MarketScreener
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Black Diamond Therapeutics (Nasdaq: BDTX) to present silevertinib Phase 2 trial results in Dec. 3 webcast - Stock Titan
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Protara (Nasdaq: TARA) Sees 100% Success in TARA-002 Pediatric LM Phase 2 Study - Stock Titan
Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women's Health - PR Newswire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis - Business Wire
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - GlobeNewswire
Cartesian (NASDAQ: RNAC) posts 100% LLDAS in SLE; expands Descartes-08 into myositis - Stock Titan
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRCSlideshow (NASDAQ:XLO) 2025-11-11 - Seeking Alpha
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - Yahoo Finance
Intellia Therapeutics Presents Positive Pooled Phase 1/2 - GlobeNewswire
Cadrenal Therapeutics, Inc. - TradingView
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for - GlobeNewswire
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart - Business Wire
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan
Beam Therapeutics to Present Updated Data from BEACON Phase - GlobeNewswire
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PR Newswire
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewswire
Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset - Seeking Alpha
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - Yahoo Finance
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules - Business Wire
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics
BlossomHill Therapeutics Presents Preliminary Findings from - GlobeNewswire
Tango Therapeutics Reports Positive Data from Ongoing Phase - GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Yahoo Finance
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 - Yahoo Finance
Perspective Therapeutics Reports 44% ORR in Cohort 2 | CATX Stock News - Stock Titan
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) - The Manila Times
RAPT Therapeutics to Report Topline Data from Phase 2 - GlobeNewswire
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting - Yahoo Finance
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - BioSpace
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
An 2 Therapeutics Inc (ANTX) 財務データ
収益
当期純利益
現金流量
EPS
0.31%
0.33%
大文字化:
|
ボリューム (24 時間):